CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and challenges that biopharma CEOs and presidents can relate to and should be aware of. To submit a CEO Corner article, please follow these guidelines.
When it comes to achieving success, a few commonalities have crystallized for me during my 30+ years in the pharma industry. Here I share five key tenets that I have found critical to success over the arc of my career.
Thirty-year pharma veteran Nancy Lurker shares her four pillars on which to build your business and why they are crucial to driving stakeholder value over the mid- to long-term.
To address the opioid epidemic we need an all-out national prevention effort akin to the one that finally began to slow the AIDS epidemic in the 1990s. Here are four actions that could help “unlock” the problem.
“Looking back on my 25 years in academic medical research, I can’t think of a single learning experience that equipped me for the world of entrepreneurship, running a public company, or interacting with the capital markets.”
Being the founder and CEO of SQZ Biotech is actually Armon Sharei’s first full-time job. He warns that although people often applaud entrepreneurship, lionize its leaders, and paint it as a glamorous adventure, that isn’t really what it’s like.
Can German, American, Chinese, and other companies worldwide work together to advance the mRNA revolution and possibly launch the new “pharmacy of the world?”
While there are many key aspects of a successful international collaboration across many time zones and great distance, in our experience — a collaboration between organizations based in the U.S. and Japan — there are a few essential elements.
Like an ocean liner changing course, the national discussion around “modern” healthcare has moved slowly away from volume toward health outcomes. As such, we in the industry need to be both innovators and advocates for change.
“I’m often asked what it takes to be a successful biotech CEO, and as one of the relatively few female CEOs in our industry, what it takes to break the proverbial glass ceiling.”
Identifying and acquiring medicines would be relatively facile; however, convincing investors that the medicines were valuable was going to be a real challenge.
Pfizer’s top scientist, Mikael Dolsten, M.D., Ph.D., talks about being hyper focused during company’s R&D turnaround amongst CEO turnover, company integrations and M&A.
Robert Hariri, M.D., Ph.D., discusses how he became friends with life coach Tony Robbins, and why Robbins decided to invest in his company.
A preview of an October 2109 issue article that discusses the results of the 2018 MassNextGen initiative that provides funding and coaching support to early-stage life sciences companies started by females.
Chief Editor Rob Wright discusses the implications of the recent Gallup poll indicating pharma presently being the most poorly regarded of all industries in the eyes of Americans.
Chief Editor Rob Wright saw glimpses into the impending opioid crisis back when he was working as a pharma sales rep in the pain management space.
